Try our beta test site

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
US Oncology Research
NSABP Foundation Inc
Alliance for Clinical Trials in Oncology
German Breast Group
Grupo Español de Investigación del Cáncer de Mama
Information provided by (Responsible Party):
AbbVie
ClinicalTrials.gov Identifier:
NCT02032277
First received: December 13, 2013
Last updated: March 2, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2026
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: March 2, 2017